SPG302

DRUG5 trials

Sponsors

Spinogenix

Conditions

Alzheimer DiseaseAlzheimer's DiseaseAmyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)Schizophrenia

Phase 1

Study of SPG302 in Healthy Volunteers and ALS Participants

CompletedNCT05882695

SpinogenixAmyotrophic Lateral Sclerosis

Start: 2023-07-03End: 2025-06-27Updated: 2025-06-29

Phase 2

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

Active, not recruitingNCT06427668

SpinogenixAlzheimer Disease

Start: 2024-07-29End: 2026-06-30Updated: 2025-08-17

Study of SPG302 in Adults With Schizophrenia

Active, not recruitingNCT06442462

SpinogenixSchizophrenia

Start: 2024-08-01End: 2026-03-01Target: 32Updated: 2026-02-06

Extension Study of Participants From SPG302-ALZ-101

TerminatedNCT06833281

SpinogenixAlzheimer's Disease

Start: 2025-03-25End: 2025-10-09Updated: 2025-12-18

Extension Study of Participants From SPG302-ALS-001

TerminatedNCT06903286

SpinogenixAmyotrophic Lateral Sclerosis (ALS)

Start: 2025-05-29End: 2025-08-31Updated: 2025-12-17